Search
ASH 2025: Kite Pharma EVP Cindy Perettie discusses today's new data for the pivotal IMMagine-1 study of the BCMA CAR-T, anito-cel. Plus, the future of dual antigen and in vivo CAR-Ts.
She highlights anito-cel's new efficacy data, and a safety profile that continues to look clean. Plus, she thinks a CD19 + CD20 dual antigen CAR-T could be best in class in the future, and why Kite acquired an in vivo CAR-T company in August for $350M. Coverage brought to you by
Dec 6
ASH 2024: Kite Pharma's global head discusses the progress of the CAR-T field, Arcellx's BCMA data, cures in CD19, autoimmune, and future targets
Cindy Perettie describes why she took the head job at Kite a little over a year ago, long-term CD19 data, tonight's BCMA update, Kite's...
Dec 8, 2024
Kite Pharma's Kristi Shaw talks cell therapy at #JPM23
Kite’s Kristi Shaw discusses BCMA, moving CAR-T into earlier lines of treatment, and focusing on improving auto programs.
Jan 10, 2023
.png){kind=logo}
